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Abstract
Background: The present study is an analysis of the frequencies of HLA-A and -B antigens and
HLA haplotypes in two groups of individuals homozygous for the two main HFE mutations (C282Y
and H63D) and a group heterozygous for the S65C mutation.
Methods: The study population includes: 1123 healthy individuals, 100 homozygous for the C282Y
mutation, 138 homozygous for the H63D mutation and 17 heterozygous for the S65C mutation.
HFE and HLA alleles were detected using DNA-based and microlymphocytotoxicity techniques
respectively.
Results: An expected significant association between C282Y and the HLA-A3/B7 haplotype was
found, but other HLA haplotypes carrying the -A3 antigen were found: HLA-A3/B62 and HLA-A3/
B44. Also, a significant association between H63D mutation and HLA-A29/B44 haplotype was
found, and again other HLA haplotypes carrying the HLA-A29 antigen were also found: HLA-A29/
B14 and HLA-A29/B62. In addition, the S65C mutation seems to be associated with a HLA
haplotype carrying the HLA-A26 antigen.
Conclusion: These findings clearly suggest that HLA-A3/B7 and HLA-A29/B44 are the ancestral
haplotypes from which the C282Y and H63D mutations originated, respectively. The frequencies
of these mutations in different populations, their geographical distribution, and the degree of the
statistical association to the ancestral haplotypes, suggest that the H63D mutation must have
occurred earlier than the C282Y mutation.
Background
Hereditary hemochromatosis (HH) is an autosomal reces-
sive disease common in northern European populations.
HH is characterized by increased iron absorption and dep-
osition in the liver, pancreas, heart, joints and pituitary
gland. Without treatment, death may occur from cirrho-
sis, primary liver cancer, diabetes or cardiomyopathy. In
1996, the HH gene (HFE) was cloned and located on the
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short arm of chromosome 6 (6p21.3) [1], 4 megabases
(Mb) telomeric to the major histocompatibility complex
(MHC). A single point mutation 845 G>A (exon 4),
changing cysteine at position 282 to tyrosine (C282Y) is
identified in 85 to 100% of patients with HH in popula-
tions of northern European descent, but it is found in only
60% of cases from Mediterranean populations [2]. Two
other mutations, 187 C>G (exon 2), a histidine to aspar-
tate change at amino acid 63 (H63D) and 193 A>T (exon
2), a serine to cysteine change at amino acid 65 (S65C)
appear to be associated with milder forms of HH and may
increase risk of disease in persons heterozygous for C282Y
mutation [3,4].
C282Y lies within a Celtic ancestral haplotype which
includes the human MHC (HLA) haplotype HLA-A3/B7
[5]. The HLA-A3/B7 haplotype was reported in HH
patients in many European and populations of European
descent [5-8] but HLA-A3/B14, HLA-A3/B35 and others
were also reported [9-11]. The predominance of the HLA-
A3 associated haplotypes on hemochromatosis chromo-
somes, and the pattern of their distribution in the world,
led Simon et al [5] to propose the founder hypothesis,
postulating that the hemochromatosis mutation was a
rare event that occurred once on a particular chromosome
which was subsequently modified by recombinations
involving both HLA-B and HLA-A alleles and population
migrations, producing the varied haplotype associations
that were described.
In contrast, the H63D substitution is not restricted to
European populations: allele frequencies greater than 5%
are found in countries bordering the Mediterranean, in
the Middle East, and in the Indian subcontinent. H63D
seems to be associated with HLA-A29 and HLA-B44
[3,12].
A few studies have been performed on the distribution of
the S65C mutation in Europe and other countries. In
1999, Barton et al [13] identified the S65C mutation in
Alabama hemochromatosis probands and found that this
mutation was linked to a haplotype characterized by HLA-
A32; and recently, Couto et al [14] found that this muta-
tion is in linkage disequilibrium with the HLA-A29/B44
haplotype.
The aim of this study is to find the HLA antigens and hap-
lotypes associated with the three main mutations in the
HFE gene in a sample of the Spanish population.
Methods
Individuals
A total of 100 unrelated individuals homozygous for the
C282Y mutation, 138 unrelated individuals homozygous
for the H63D mutation and 17 individuals heterozygous
for the S65C mutation were selected for this study. These
were subjects in whom HFE genotyping has been previ-
ously performed on a medical care basis because of a pre-
sumptive diagnosis of hemochromatosis. In addition,
1113 unrelated, apparently healthy subjects were used as
controls for the study. In addition, HLA typing was per-
formed in 230 individuals whom HFE genotyping was
negative for the three mutations.
HLA-A and -B typing
HLA-class I typing was performed on freshly collected
venous blood samples by the standard complement-
dependent microlymphocytotoxicity assay using com-
mercially available alloantisera.
DNA extraction and HFE amplification
Genomic DNA from whole blood samples was extracted
by standard protocols. Polymerase chain reaction (PCR)
with the pair of primers HEMEx2-5' (5'-CTT TGG GCT
ACG TGG ATG ACC) and HEMEx2-3' (5'-CTG GCT TGA
AAT TCT ACT GGA AAC C) was used to amplify exon 2 of
the HFE gene. To amplify exon 4, a second set of oligonu-
cleotides was used: HEMEx4-5' (5'-GGT GTC GGG CCT
TGA ACT ACT ACC) and HEMEx4-3' (5'-A CAT ACC CCA
GAT CAC AAT GAG G).
The following conditions were used for the PCR reactions:
five minutes denaturation at 94°C, 40 cycles of 15 sec-
onds denaturation at 95°C, 15 seconds annealing at 57°C
and 30 seconds extension at 72°C. PCR products coming
from exons 2 and 4 were 101 and 228 base pairs (bp),
respectively.
Digestion with mutation-specific restriction endonuclease
Following the PCR amplifications, aliquots (17 µl) of the
reaction mixture were digested with the restriction endo-
nucleases Bcl I (exon 2), Hinf I (exon 2) and Rsa I (exon 4)
for 3 hours following the protocol recommended by the
manufacturer (Promega, Madison, WI). The H63D muta-
tion destroys the Bcl I site in the 101 bp PCR product, so
while normal DNA is cut into two fragments of 38 and 63
bp, the mutated DNA is not cut. The S65C mutation
destroys the Hinf I site in the 101 bp PCR product, so
while normal DNA is cut into two fragments of 47 and 54
bp, the mutated DNA is not cut. The C282Y mutation cre-
ates a new Rsa I site, the 228 bp DNA product digested
with this enzyme is cut into two fragments of 145 and 83
bp in the normal allele, while in the mutated DNA three
fragments of 145, 29 and 54 bp are generated after diges-
tion. The digested products were size resolved in 10% acr-
ylamide gel and detected by staining with ethidium
bromide.BMC Medical Genetics 2004, 5:25 http://www.biomedcentral.com/1471-2350/5/25
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Statistical analysis
Allele and haplotype frequencies were estimated using Arle-
quin V2.0 software [15]. The haplotype frequencies were
computed using the Expectation-Maximization algorithm
[16]; this procedure is an interactive process aimed at obtain-
ing maximum-likelihood estimates of haplotype frequencies
from multi-locus genotype data when the gametic phase is
unknown. The existence of association between HFE muta-
tions and HLA-A and -B alleles and haplotypes was calcu-
lated by 2 × 2 comparison tables and p values were corrected
according to the number of alleles or haplotypes compared
[17] and using Yates corrected Chi2 and Fisher's tests. Odds
ratios were calculated as previously described [18].
Results
The allele frequencies of the HLA-A and -B antigens found
in the C282Y carriers group, in comparison with the fre-
quencies in the control population are listed in Table 1. As
expected, significant associations were found for HLA-A3
and -B7, but HLA-B62 also shows significant association.
The association of HLA-A3 is stronger than that of HLA-B7
or -B62. The frequencies of the HLA-A/B haplotypes in the
homozygous group in comparison with the haplotype fre-
quencies in the control population are listed in Table 2.
Three haplotypes are significantly associated with the
C282Y mutation: HLA-A3/B7, HLA-A3/B62 and HLA-A3/
B44.
Table 2: Frequencies of HLA-A/B haplotypes in the two groups homozygous for H63D and C282Y in comparison with the control group.
HAPLOTYPE H63D HAPLOTYPES 
Freq (n = 276)
p OR C282Y HAPLOTYPES 
Freq (n = 200)
p OR CONTROLS 
Freq (n = 2226)
A1/B8 0.02513 N.S. 0.01500 N.S. 0.0246
A2/B7 0.03612 N.S. 0.02859 N.S. 0.0239
A2/B44 0.08254 N.S. 0.04037 N.S. 0.0443
A2/B51 0.04839 N.S. 0.00000 0.0404
A2/B35 0.01545 N.S. 0.03543 N.S. 0.0258
A3/B14 0.00000 0.00000 0.0005
A3/B7 0.00725 N.S. 0.20275 <10-7 7.29 0.0343
A3/B62 0.00000 0.03379 10-5 16.11 0.0024
A3/B44 0.00409 N.S. 0.08989 <10- 12.13 0.0079
A11/B27 0.01812 N.S. 0.00000 0.0064
A11/B35 0.00362 N.S. 0.00862 N.S. 0.0204
A24/B35 0.00794 N.S. 0.01478 N.S. 0.0233
A29/B44 0.13261 <10-7 3.93 0.02999 N.S. 0.0378
A29/B14 0.01449 <0.01 32.7 0.00000 0.0005
A29/B62 0.01591 <0.01 32.7 0.00000 0.0005
A30/B18 0.01087 N.S. 0.00000 0.0278
A33/B14 0.00000 0.00500 N.S. 0.0121
Freq: Frequency n: Total number of haplotypes in each group OR: Odds ratio p: Significance level N.S.: Not significant
Table 1: Allele frequencies of HLA-A and HLA-B antigens in the C282Y homozygous group in comparison with the control group.
C282Y HOMOZYGOTES CONTROLS C282Y HOMOZYGOTES CONTROLS
HLA Freq (n = 200) OR p Freq (n = 2226) HLA Freq (n = 200) OR p Freq (n = 2226)
A1 0.070 0.69 N.S. 0.097 B8 0.035 0.81 N.S. 0.044
A3 0.425 6.23 <10-7 0.106 B7 0.260 3.67 <10-7 0.089
B62 0.075 2.74 0.030 0.028
A29 0.035 0.54 N.S. 0.062 B44 0.170 1.19 N.S. 0.146
A30 0.010 0.16 0.093 0.060 B18 0.015 0.27 0.120 0.088
A2 0.195 0.67 N.S. 0.264 B35 0.095 0.77 N.S. 0.119
A11 0.060 0.75 N.S. 0.078 B51 0.055 0.60 N.S. 0.088
A26 0.020 0.42 N.S. 0.046 B49 0.025 0.67 N.S. 0.036
A28 0.025 0.59 N.S. 0.041 B60 0.015 0.42 N.S. 0.035
A32 0.020 0.57 N.S. 0.034 B14 0.010 0.28 N.S. 0.035
A23 0.030 0.95 N.S. 0.031 B38 0.010 0.33 N.S. 0.029
A33 0.010 0.36 N.S. 0.027 B27 0.025 0.88 N.S. 0.028
A25 0.020 0.97 N.S. 0.020 B50 0.005 0.21 N.S. 0.023
A31 0.025 1.56 N.S. 0.016 B65 0.015 0.64 N.S. 0.023
Freq: Frequency n: Total number of alleles in each group OR: Odds ratio p: Significance level N.S.: Not significantBMC Medical Genetics 2004, 5:25 http://www.biomedcentral.com/1471-2350/5/25
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The allele frequencies of the HLA-A and -B antigens in the
H63D homozygous group in comparison with the fre-
quencies in the control population are listed in Table 3.
Significant associations were found for HLA-A29 and -
B44. Again, the association of the HLA-A antigen (HLA-
A29) is stronger than HLA-B44. The frequencies of the
HLA-A/B haplotypes are also listed in Table 2, and three
HLA-A/B haplotypes (with the same HLA-A antigen, HLA-
A29) are significantly associated with the H63D mutation:
HLA-A29/B44, HLA-A29/B14 and HLA-A29/B62.
From the 17 individuals heterozygous for the S65C muta-
tion, 7 (20%) were HLA-A26 versus 4.6% found in the
control population (p = 0.02, OR = 5.29). No association
with HLA-B has been found.
The significant associations did not change if we used a
control group of 230 individuals without HFE mutations.
Discussion
Populations of homozygous individuals for C282Y and
H63D are optimal groups to study the HLA haplotypes in
which these mutations preferentially appear. To our
knowledge, Barton [19] and the present work are the only
studies of associations between HFE mutations and HLA
antigens and haplotypes in homozygous probands. The
paper by Barton and Acton [19] presents haplotype fre-
quencies assessed by family studies where phase could be
set; in our paper, the haplotype frequences are estimated
because the probands and controls are unrelated individ-
uals. The low frequency of the S65C mutation makes the
sampling of homozygous probands difficult and imposes
the use of heterozygous individuals for the analysis.
C282Y and HLA
The strong association between the HLA-A3/B7 haplotype
and the C282Y mutation indicates that this haplotype is
the main one associated with this mutation in the Spanish
population. However, other haplotypes are also associ-
ated: HLA-A3/B62 and HLA-A3/B44. This finding sup-
ports the founder hypothesis of Simon et al [5]: the
ancestral haplotype where the C282Y mutation occurred
on the ancestral haplotype HLA-A3/B7 and subsequent
recombinations involving both HLA-B and HLA-A alleles
produced the varied haplotype associations that have
been found. Thus, we found many HLA-A/B haplotypes in
our C282Y group, but only three HLA-A3 bearing haplo-
types are statistically associated with this mutation. The
two less frequent haplotypes (HLA-A3/B44 and HLA-A3/
B62) have been observed in other populations in associa-
tion with HH [20,21].
In addition, the high frequency of the HLA-A3/B7 haplo-
type makes other HLA antigens and haplotypes have
reduced frequencies in respect to the controls. It is inter-
esting to see that haplotypes with high-frequency in the
Spanish population, such as HLA-A30/B18 and HLA-A2/
B51 are absent in the C282Y homozygous group (Table
2). These HLA haplotypes are not contaminated  by the
C282Y mutation, and up until now, these haplotypes may
be considered as protector haplotypes.
H63D and HLA
Porto et al [3] and Cardoso et al [22] found individual
associations between HLA-A29 and non-classical forms of
iron overload in linkage disequilibrium with H63D, and
a strong linkage disequilibrium between H63D and all
Table 3: Allele frequencies of HLA-A and HLA-B antigens in the H63D homozygous group in comparison with the control group.
H63D HOMOZYGOTES CONTROLS H63D HOMOZYGOTES CONTROLS
HLA Freq (n = 276) OR p Freq (n = 2226) HLA Freq (n = 276) OR p Freq (n = 2226)
A1 0.061 0.60 N.S. 0.097 B8 0.050 1.14 N.S. 0.044
A3 0.086 0.80 N.S. 0.106 B7 0.068 0.75 N.S. 0.089
B62 0.028 1.00 N.S. 0.028
A29 0.199 3.65 <10-7 0.062 B44 0.264 2.10 2.10-5 0.146
A30 0.036 0.58 N.S. 0.060 B18 0.086 0.98 N.S. 0.088
A2 0.286 1.12 N.S. 0.264 B35 0.076 0.60 N.S. 0.119
A11 0.036 0.44 N.S. 0.078 B51 0.097 1.12 N.S. 0.088
A26 0.029 0.61 N.S. 0.046 B49 0.032 0.89 N.S. 0.036
A28 0.021 0.52 N.S. 0.041 B60 0.011 0.30 N.S. 0.035
A32 0.039 1.16 N.S. 0.034 B14 0.014 0.40 N.S. 0.035
A23 0.047 1.52 N.S. 0.031 B38 0.032 1.10 N.S. 0.029
A33 0.007 0.26 N.S. 0.027 B27 0.036 1.29 N.S. 0.028
A25 0.032 1.60 N.S. 0.020 B50 0.018 0.76 N.S. 0.023
A31 0.011 0.67 N.S. 0.016 B65 0.039 1.74 N.S. 0.023
Freq: Frequency n: Total number of alleles in each group OR: Odds ratio p: Significance level N.S.: Not significantBMC Medical Genetics 2004, 5:25 http://www.biomedcentral.com/1471-2350/5/25
Page 5 of 6
(page number not for citation purposes)
A29 containing haplotypes assigned in a large population
of normal portuguese families.
In the present work we found a strong association
between the HLA-A29/B44 haplotype and the H63D
mutation. Our finding agrees with the association of HLA-
A29/B12(44) and hemochromatosis described in the
Danish population [21].
H63D and HLA-A29-bearing haplotypes follow a pattern
of associations similar to that described for C282Y and
HLA-A3-bearing haplotypes. This promotes speculation
that HLA-A29/B44 is the ancestral haplotype from which
the H63D mutation emerged, since other HLA-A29 carry-
ing haplotypes are also statistically associated with the
mutation (HLA-A29/B14 and HLA-A29/B62, see Table 2),
confirming the results reported by Cardoso et al [22] in
the normal Portuguese population. Studies in other pop-
ulations might lend support to whether HLA-A29/B44 is
the ancestral haplotype of the H63D mutation, and HLA-
A29/B14 and HLA-A29/B62 are specific Spanish haplo-
types associated with H63D mutation.
C282Y and H63D mutations: which one is older?
In an attempt to establish the relative age of C282Y and
H63D mutations, we have analysed the geographical dis-
tribution, allele frequencies and HLA haplotype associa-
tions for each mutation, assuming that the mutations
ocurred once and that its age is directly proportional to its
geographical spread, its frequency in the population, and
the number of HLA haplotypes to which they are linked.
On the other hand, a strong association of a particular
HFE mutation to a particular HLA haplotype could mean
that the mutation arose more recently, since the lower
number of ruptures and recombinations of the original
haplotype would reflect that a shorter time has passed.
Merryweather-Clarke et al [23] analysed 2978 samples
from probands distributed world-wide and showed that
the C282Y mutation was most prevalent in northern
European populations and absent from samples of non-
European subjects (Africans, Asians, Australasians and
Americans). In contrast, the H63D mutation is not
restricted to European populations, being found in coun-
tries bordering the Mediterranean, in the Middle East and
in the Indian subcontinent, and its allele frequency is
higher than that of the C282Y mutation [23]. Our analysis
of C282Y and H63D homozygous groups yielded a higher
number of HLA haplotypes in association with the H63D
mutation; and the frequency of HLA-A3/B7 in the C282Y
homozygous group is 20%, while the frequency of HLA-
A29/B44 in the H63D homozygous group is 13% (see
table 2), reflecting that the HLA-A29/B44/H63D haplo-
type has suffered more recombinations than HLA-A3/B7/
C282Y, and therefore, that HLA-A29/B44/H63D is older
[24].
Altogether, these features suggest that the H63D mutation
may have occurred earlier than the C282Y mutation, as
has been previously proposed in studies from Italian pop-
ulations [25,26].
S65C and HLA
Few studies have been performed on the distribution, fre-
quency and HLA association of the S65C mutation in
Europe and other continents. Barton et al [13] described
the linkage of the S65C mutation to a HLA-A32 haplotype
in hemochromatosis probands from Alabama. Surpris-
ingly, Couto et al [14] found the linkage of S65C (and not
H63D) to the HLA-A29/B44 haplotype in a population
from the Azores, although only 5 H63D homozygous and
9 S65C heterozygous individuals were studied in that
work.
In the present work we find that the S65C mutation seems
to be linked to HLA-A26 in the Spanish population. Fur-
ther studies in other populations and with more S65C-
bearing haplotypes are necessary to shed light on the gen-
eration of the S65C mutation.
Conclusions
We have found that, in the Spanish population, the three
main  HFE  mutations: C282Y, H63D and S65C, are in
linkage disequilibrium with HLA haplotypes carrying the
HLA-A3, -A29 and -A26 alleles, respectively. In addition,
the ancestral HLA haplotypes from which C282Y and
H63D mutations were originated are HLA-A3/B7 and
HLA-A29/B44, respectively, and H63D is older than
C282Y. Further studies in other populations using
homozygous individuals for HFE mutations will help to
identify the associated ancestral and specific haplotypes.
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